Voriconazole
- TRADE NAME: Vfend (Pfizer)
- INDICATIONS: Invasive aspergillosis
- CLASS: Antibiotic, triazole
- HALF-LIFE: 6–24 hours (dose dependent)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abiraterone, Astemizole, Atazanavir, Barbiturates, Boceprevir, Carbamazepine, Clopidogrel, Crizotinib, Diclofenac, Dronedarone, Ergot alkaloids, Everolimus, Ixabepilone, Lapatinib, Lopinavir, Meloxicam, Methylergonovine, Mifepristone, Nilotinib, Omeprazole, Pantoprazole, Pimozide, Quinidine, Rifabutin, Rifampin, Rifapentine, Rilpivirine, Ritonavir, Rivaroxaban, Romidepsin, Ruxolitinib, Sirolimus, Solifenacin, Sunitinib, Telaprevir, Temsirolimus, Ticagrelor, Vemurafenib
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
OCULAR
LOCAL
OTHER
Click on this DRUG REVIEW ARTICLE tab (above) to see a review of voriconazole in the Informa Healthcare journal Expert Opinion on Drug Safety (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric